[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578249":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":38,"centralContacts":39,"locations":45,"responsibleParty":58,"collaborators":38,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":38,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":38,"overallStatus":83,"whyStopped":38,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Second Hospital of Shanxi Medical University","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Low dose sufentanil group","EXPERIMENTAL","The concentration of sufentanil is set to concentration for the low-dose group",[13],"Drug: Sufentanil injection",{"label":15,"type":10,"description":16,"interventionNames":17},"Medium-dose sufentanil group","The concentration of sufentanil is set to medium-dose concentration for the low-dose group",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"High dose sufentanil group","The concentration of sufentanil is set to high concentration for the low-dose group",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Blank control group","No analgesics were given",[26],"Drug: Placebo",[28,35],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Sufentanil injection","Different concentrations of sufentanil were administered to three different subgroups of patients in the same way",[19,9,15],[34],"Sufentanil dose",{"type":29,"name":36,"description":36,"armGroupLabels":37,"otherNames":38},"Placebo",[23],null,[40],{"name":41,"role":42,"phone":43,"phoneExt":38,"email":44},"Jvan Wu, Docter","CONTACT","15235361727","13513520761@163.com",[46],{"facility":5,"status":38,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":38},"Taiyuan","Shanxi","030001","China","CN",{"type":53,"coordinates":54},"Point",[55,56],112.56028,37.86944,{"lat":56,"lon":55},{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":38,"oldOrganization":38},"PRINCIPAL_INVESTIGATOR","Zheng Guo","Professor","100578249","sufentanil-in-patients-with-lower-extremity-fracture-surgery-myocardial-damage-function-study-100578249",false,"NCT06808841","Sufentanil in Patients With Lower Extremity Fracture Surgery Myocardial Damage Function Study","Sufentanil is Paired Via the BMP6\u002FSMAD Pathway Cardiac Injury in Lower Extremity Fracture Surgery Function Study","Sipwlefsmdfs","Inclusion Criteria:\n\n* There were 160 patients aged 18-65 years and older who needed surgery for lower extremity fracture.\n* ASA grades I to III, gender is not limited.\n\nExclusion Criteria:\n\n* Patients with acute myocardial infarction in the last 6 months, those with a history of heart failure, and those with elevated troponin levels before injury.\n* Old fracture\n* Stroke patients\n* Liver cirrhosis, kidney failure\n* Serious systemic infections, alcoholism, drug dependence\n* Pathological fracture\n* Use of glucocorticoids in the past one month\n* Diabetic",true,"ALL","18 Years","65 Years",{"count":75,"type":76},160,"ESTIMATED","INTERVENTIONAL",[79],"NA","1. To analyze the association of different doses of opioids on myocardial injury\u002Fprotection through BMP-6\u002FSMAD pathway.\n2. To observe the effect of different doses of opioids on the expression of BMP-6 in bone marrow.\n3. To investigate the relationship between different doses of opioids and BMP-6 and perioperative cardiovascular adverse events in patients with lower extremity fracture surgery.",[82],"Myocardial Injury","NOT_YET_RECRUITING","2025-02-04",{"date":86,"type":87},"2025-02-05","ACTUAL",{"date":86,"type":76},{"date":90,"type":76},"2025-05-10",{"name":5,"class":6},1]